drugset
drugset / Trial / NCT07372703

Study of the Safety, Tolerability, Pharmacokinetics of VV913 Capsules in Chinese Healthy Participants

NCT07372703 ↗

Phase 1 Recruiting 56 enrolled Vigonvita Life Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV913 Capsules in healthy adults.

Timeline

Start
2026-01-29
Primary completion
2026-09
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject VV913 Unknown 1 mg Oral
Subject VV913 Unknown 2 mg Oral
Subject VV913 Unknown 4 mg Oral
Subject VV913 Unknown 8 mg Oral
Subject VV913 Unknown 15 mg Oral
Subject VV913 Unknown 25 mg Oral
Subject VV913 Unknown 40 mg Oral

Indications

No indication recorded.